ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 750 participants.

Also called NCT06716021

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 750 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06716021
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada, Netherlands (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06716021. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-20 (actual); primary completion 2028-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3
Acronym
ReVeRA-301
Intervention (Drug)
Placebo
Intervention (Drug)
Etripamil
Lead sponsor
Milestone Pharmaceuticals Inc. (class: other)

Record details

Record id
cardio:ct-nct06716021
Content hash
0ec32defd44123206e1a2302a3eddfa0455626c0bdc9c6c40438a147d60186e2